Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AVNS NYSE:ENOV NASDAQ:NVCR NYSE:WRBY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVNSAVANOS MEDICAL$12.25-0.2%$12.43$11.68▼$25.36$567.88M1.12385,935 shs350,728 shsENOVEnovis$35.94+1.1%$33.00$28.83▼$49.83$2.03B1.7900,307 shs1.22 million shsNVCRNovoCure$18.46+1.5%$17.66$14.17▼$34.13$2.03B0.721.13 million shs652,317 shsWRBYWarby Parker$22.23-0.2%$20.44$12.46▼$28.68$2.33B2.092.00 million shs1.82 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVNSAVANOS MEDICAL-0.49%-0.64%-2.85%-1.29%-36.16%ENOVEnovis+2.19%+6.23%+7.77%+10.95%-18.86%NVCRNovoCure+3.88%+1.73%+7.63%+13.12%+8.21%WRBYWarby Parker-0.62%+1.46%-0.86%+46.72%+41.73%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVNSAVANOS MEDICAL1.5416 of 5 stars0.03.00.00.00.51.72.5ENOVEnovis3.5898 of 5 stars3.43.00.00.03.21.71.9NVCRNovoCure3.604 of 5 stars3.41.00.04.51.91.70.0WRBYWarby Parker2.0753 of 5 stars2.33.00.00.02.03.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVNSAVANOS MEDICAL 0.00N/AN/AN/AENOVEnovis 2.80Moderate Buy$55.6054.70% UpsideNVCRNovoCure 2.71Moderate Buy$32.4375.67% UpsideWRBYWarby Parker 2.53Moderate Buy$22.882.92% UpsideCurrent Analyst Ratings BreakdownLatest AVNS, ENOV, NVCR, and WRBY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025WRBYWarby ParkerJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Perform7/10/2025WRBYWarby ParkerCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform7/8/2025ENOVEnovisEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$48.00 ➝ $46.007/8/2025NVCRNovoCureLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.006/27/2025NVCRNovoCurePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$34.005/29/2025WRBYWarby ParkerPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$20.00 ➝ $25.005/22/2025WRBYWarby ParkerRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$18.00 ➝ $21.005/21/2025WRBYWarby ParkerCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/21/2025WRBYWarby ParkerLoop CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/21/2025WRBYWarby ParkerCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$17.00 ➝ $22.005/21/2025WRBYWarby ParkerStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$18.00 ➝ $21.00(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVNSAVANOS MEDICAL$687.80M0.82$11.78 per share1.04$18.03 per share0.68ENOVEnovis$2.11B0.97$19.43 per share1.85$45.10 per share0.80NVCRNovoCure$605.22M3.40N/AN/A$3.33 per share5.54WRBYWarby Parker$771.32M3.01$0.34 per share65.60$3.35 per share6.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVNSAVANOS MEDICAL-$392.10M-$8.37N/A7.08N/A-55.80%6.26%4.63%7/30/2025 (Estimated)ENOVEnovis-$825.49M-$13.9511.3211.27N/A-37.65%5.99%3.44%8/6/2025 (Estimated)NVCRNovoCure-$168.63M-$1.51N/AN/AN/A-26.41%-45.46%-13.34%7/24/2025 (Estimated)WRBYWarby Parker-$20.39M-$0.12N/A222.25N/A-1.79%-2.48%-1.29%8/6/2025 (Estimated)Latest AVNS, ENOV, NVCR, and WRBY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025ENOVEnovis$0.74N/AN/AN/A$555.80 millionN/A7/30/2025Q2 2025AVNSAVANOS MEDICAL$0.18N/AN/AN/A$165.50 millionN/A7/24/2025Q2 2025NVCRNovoCure-$0.40N/AN/AN/A$153.87 millionN/A5/8/2025Q1 2025ENOVEnovis$0.74$0.81+$0.07-$0.98$558.80 million$558.83 million5/6/2025Q1 2025AVNSAVANOS MEDICAL$0.19$0.26+$0.07$0.14$161.75 million$167.50 million4/24/2025Q1 2025NVCRNovoCure-$0.47-$0.31+$0.16-$0.31$147.57 million$154.99 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVNSAVANOS MEDICALN/AN/AN/AN/AN/AENOVEnovisN/AN/AN/AN/AN/ANVCRNovoCureN/AN/AN/AN/AN/AWRBYWarby ParkerN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVNSAVANOS MEDICAL0.122.571.56ENOVEnovis0.522.551.32NVCRNovoCure0.271.471.41WRBYWarby ParkerN/A2.702.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVNSAVANOS MEDICAL95.17%ENOVEnovis98.45%NVCRNovoCure84.61%WRBYWarby Parker93.24%Insider OwnershipCompanyInsider OwnershipAVNSAVANOS MEDICAL2.64%ENOVEnovis2.70%NVCRNovoCure5.52%WRBYWarby Parker18.24%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVNSAVANOS MEDICAL2,22746.24 million45.02 millionOptionableENOVEnovis7,36757.12 million55.58 millionOptionableNVCRNovoCure1,488111.49 million105.33 millionOptionableWRBYWarby Parker3,780104.50 million85.44 millionOptionableAVNS, ENOV, NVCR, and WRBY HeadlinesRecent News About These CompaniesWarby Parker (NYSE:WRBY) Receives "Market Perform" Rating from JMP SecuritiesJuly 10 at 9:55 AM | marketbeat.comWarby Parker (NYSE:WRBY) Stock Rating Lowered by Citizens JmpJuly 10 at 8:52 AM | marketbeat.comWarby Parker Inc. Stock Grades | WRBY - Barron'sJuly 10 at 4:35 AM | barrons.comWarby Parker Inc. (NYSE:WRBY) Receives $22.88 Average PT from AnalystsJuly 9 at 3:35 AM | americanbankingnews.comWinners And Losers Of Q1: Warby Parker (NYSE:WRBY) Vs The Rest Of The Beauty and Cosmetics Retailer StocksJuly 8 at 11:55 AM | msn.comWarby Parker Inc. (NYSE:WRBY) Receives Consensus Rating of "Moderate Buy" from BrokeragesJuly 6, 2025 | americanbankingnews.comWarby Parker Inc. (NYSE:WRBY) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJuly 6, 2025 | marketbeat.com11,751 Shares in Warby Parker Inc. (NYSE:WRBY) Acquired by Diversified Trust CoJuly 2, 2025 | marketbeat.comWhat Makes Warby Parker (WRBY) an Attractive Investment?June 30, 2025 | finance.yahoo.comBessemer Group Inc. Has $1.17 Million Stock Position in Warby Parker Inc. (NYSE:WRBY)June 30, 2025 | marketbeat.comWRBY - Warby Parker Inc Ordinary Shares - Class A Chart - MorningstarJune 28, 2025 | morningstar.comMThe 5 Most Interesting Analyst Questions From Warby Parker’s Q1 Earnings CallJune 27, 2025 | msn.comWarby Parker (NYSE:WRBY) Stock Price Down 3.7% - Here's What HappenedJune 26, 2025 | marketbeat.comSG Americas Securities LLC Buys Shares of 33,023 Warby Parker Inc. (NYSE:WRBY)June 22, 2025 | marketbeat.comWarby Parker (WRBY): Buy, Sell, or Hold Post Q1 Earnings?June 20, 2025 | msn.comRiverwater Partners LLC Invests $460,000 in Warby Parker Inc. (NYSE:WRBY)June 20, 2025 | marketbeat.comVaughan Nelson Investment Management L.P. Trims Stake in Warby Parker Inc. (NYSE:WRBY)June 15, 2025 | marketbeat.comTech Giants Partner With Retailers As Smart Glasses Battle Heats UpJune 12, 2025 | forbes.comWarby Parker eyes space at trendy Raleigh shopping centerJune 11, 2025 | bizjournals.comWarby Parker Inc. (NYSE:WRBY) Given Consensus Rating of "Moderate Buy" by BrokeragesJune 11, 2025 | marketbeat.comWRBY Q1 Earnings Call: Management Details Tariff Mitigation, Store Expansion, and Pricing ActionsJune 10, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseEnovix Shares Hit 6-Month High; Long-Term Highs to FollowBy Thomas Hughes | July 10, 2025View Enovix Shares Hit 6-Month High; Long-Term Highs to FollowAVNS, ENOV, NVCR, and WRBY Company DescriptionsAVANOS MEDICAL NYSE:AVNS$12.25 -0.03 (-0.24%) Closing price 03:59 PM EasternExtended Trading$12.26 +0.01 (+0.08%) As of 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avanos Medical, Inc., a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides a portfolio of non-opioid pain solutions, including surgical pain and recovery products, such as ON-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy; OrthogenRx's knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.Enovis NYSE:ENOV$35.94 +0.38 (+1.07%) Closing price 03:59 PM EasternExtended Trading$35.94 0.00 (0.00%) As of 06:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.NovoCure NASDAQ:NVCR$18.46 +0.27 (+1.48%) Closing price 04:00 PM EasternExtended Trading$18.42 -0.04 (-0.22%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.Warby Parker NYSE:WRBY$22.22 -0.05 (-0.20%) Closing price 03:59 PM EasternExtended Trading$22.54 +0.32 (+1.44%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Warby Parker Inc. provides eyewear products in the United States and Canada. The company offers eyeglasses, sunglasses, light-responsive lenses, blue-light-filtering lenses, non-prescription lenses, and contact lenses. It also provides accessories, such as cases, lenses kit with anti-fog spray, pouches, and anti-fog lens spray through its retail stores, website, and mobile apps. In addition, the company offers eye exams and vision tests. Warby Parker Inc. was incorporated in 2009 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain BigBear.ai: Why a 90% Rally Could Be Just the Start Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Alphabet: Technical Momentum Is Starting to Turn Boeing's Rebound Is Well Underway—But Is It Too Late? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
